US FDA approves Elanco's skin disease treatment for dogs
Adds details on study in paragraphs 5, 6
By Sriparna Roy
Sept 19 (Reuters) -The U.S. Food and Drug Administration has approved Elanco Animal Health's ELAN.N skin disease treatment for dogs, the health regulator's website showed on Thursday, sending the company's shares up 2% in afternoon trade.
The oral drug, Zenrelia, aims to control pruritus, or itching, associated with allergic dermatitis and to control atopic dermatitis in dogs that are at least 12 months old.
Zenrelia, an immunosuppressant, is administered once daily, with or without food.
Elanco considers Zenrelia as one of its potential blockbusters. It is the company's first product in the market related to skin disease treatments for dogs, that include Zoetis' ZTS.N oral treatment Apoquel.
In a head-to-head study conducted in 338 dogs, Zenrelia showed greater relief from itching and skin lesions over time than Apoquel, Elanco said.
The study was conducted by the company for the drug's submission, to be reviewed, in the European Union.
The company plans to launch Zenrelia in the coming days, Elanco CEO Jeff Simmons said.
Elanco will price Zenrelia around 20% lower than Apoquel, Simmons said, adding that there will be some additional savings as Elanco's drug is dosed once-daily, while Apoquel is dosed twice-daily in the initial phase of treatment.
Zoetis did not immediately respond to a request for a comment on pricing.
Zenrelia belongs to a class of drugs known as JAK inhibitors, which block inflammation-causing enzymes known as Janus kinases.
In June, Elanco cautioned that the boxed warning on the drug label could slow its adoption in the United States.
The FDA approval for Zenrelia carries a boxed warning stating that dogs should not be vaccinated at least 28 days before and after treatment with the drug, due to the risk of fatal vaccine-induced disease and inadequate immune response to vaccines.
Reporting by Sriparna Roy and Puyaan Singh in Bengaluru; Editing by Alan Barona
Eng oxirgi yangiliklar
Javobgarlikdan voz kechish: XM Group korxonalari har biri faqat ijro xizmatlarini koʻrsatadi va onlayn savdo platformamizdan foydalanish huquqini beradi, bu odamga veb-saytda yoki veb-sayt orqali mavjud boʻlgan kontentni koʻrish va/yoki undan foydalanishga ruxsat beradi hamda uni oʻzgartirishga moʻljallanmagan va uni oʻzgartirmaydi yoki kengaytirmaydi. Bunday kirish va foydalanish huquqi doimo quyidagilarga boʻysunadi: (i) Shartlar va qoidalar; (ii) Risklar haqida ogohlantirish; va (iii) Javobgarlikni toʻliq rad etish. Shuning uchun bunday kontent umumiy maʼlumot sifatida taqdim etiladi. Xususan, shuni esda tutingki, bizning onlayn savdo platformamiz mazmuni moliyaviy bozorlarda biror bitimni amalga oshirishga oid maslahat yoki taklif emas. Har qanday moliyaviy bozorda savdo qilish sizning kapitalingiz uchun jiddiy risk darajasini oʻz ichiga oladi.
Onlayn savdo platformamizda chop etilgan barcha materiallar faqat taʼlim/axborot maqsadlari uchun moʻljallangan va unda moliyaviy, investitsiya soligʻi yoki savdo maslahatlari va tavsiyalar; yoki bizning savdo narxlarimizning qaydlari; yoki har qanday moliyaviy vositalar bilan bitim tuzish maslahati yoki taklifi; yoki sizga kerak boʻlmagan moliyaviy reklama aksiyalari hisoblanmaydi
Har qanday uchinchi tomon kontenti, shuningdek XM tomonidan tayyorlangan kontent, masalan: fikrlar, yangiliklar, tadqiqotlar, tahlillar, narxlar va boshqa maʼlumotlar yoki bu veb-saytda joylashgan uchinchi tomon saytlariga havolalar umumiy bozor sharhi sifatida "boricha" taqdim etiladi va investitsiya maslahatini tashkil etmaydi. Har qanday kontent investitsiya tadqiqoti sifatida talqin qilinsa, siz bunday kontentni investitsiya tadqiqotlarining mustaqilligini ragʻbatlantirish uchun moʻljallangan qonun talablariga muvofiq moʻljallanmagan va tayyorlanmaganligini eʼtiborga olishingiz va qabul qilishingiz kerak, shuning uchun unga tegishli qonunlar va qoidalarga muvofiq marketing kommunikatsiyasi sifatida qaraladi. Mustaqil boʻlmagan investitsiya tadqiqoti va yuqoridagi maʼlumotlarga oid risk haqida ogohlantirishimizni oʻqib chiqqaningizga va tushunganingizga ishonch hosil qiling, unga bu yerdan kirish mumkin.
